Fuchs, Michael
Jacob, Anne Sophie
Kaul, Helen
Kobe, Carsten http://orcid.org/0000-0002-2909-0826
Kuhnert, Georg
Pabst, Thomas http://orcid.org/0000-0002-6055-5257
Greil, Richard
Bröckelmann, Paul J. http://orcid.org/0000-0001-9662-9900
Topp, Max S.
Just, Marianne
Hertenstein, Bernd
Soekler, Martin
Vogelhuber, Martin
Zijlstra, Josée M.
Keller, Ulrich Bernd http://orcid.org/0000-0002-8485-1958
Krause, Stefan W. http://orcid.org/0000-0002-5259-4651
Dührsen, Ulrich
Meissner, Julia http://orcid.org/0000-0003-1908-2096
Viardot, Andreas
Eich, Hans-Theodor
Baues, Christian
Diehl, Volker
Rosenwald, Andreas
Buehnen, Ina
von Tresckow, Bastian http://orcid.org/0000-0003-1410-4487
Dietlein, Markus
Borchmann, Peter
Engert, Andreas
Eichenauer, Dennis A. http://orcid.org/0000-0002-1927-3514
Funding for this research was provided by:
Sanofi-Genzyme, Takeda
Employment/leadership position (University Hospital of Cologne, Head of the GHSG Trial Coordination Centre), honorarium
Takeda Medical Research Foundation
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
BeiGene, MSD Stemline
Gilead Sciences
Miltenyi Biotec
Novartis
Roche
Amgen
Pfizer
Merck & Co., Inc. | Merck Sharp and Dohme
AbbVie
AstraZeneca
allogene, Cerus, incyte, IQVIA, Noscendo, Pentixapharm,
Article History
Received: 2 August 2023
Revised: 25 September 2023
Accepted: 5 October 2023
First Online: 16 October 2023
Competing interests
: MF: Employment/leadership position (University Hospital of Cologne, Head of the GHSG Trial Coordination Centre), honorarium (Celgene, BMS, Takeda, Affimed, Lukon, Janssen). ASJ: No personal disclosures. HK: No personal disclosures. CK: No personal disclosures. TP: No personal disclosures. PJB: Personal disclosures regarding consulting (BeiGene, Takeda), honorarium (BeiGene, BMS, MSD Stemline, Takeda), financing of scientific studies (BeiGene, BMS, MSD, Takeda), other financial relations (Celgene (travel)). MS: No personal disclosures. MV: No personal disclosures. UD: Personal disclosures regarding honorarium (Amgen, Avencell (DSMB activities)). JM: Personal disclosures regarding consulting (MSD) and other financial relations (Travel support Takeda, MSD, BMS). CB: No personal disclosures. VD: No personal disclosures. AR: No personal disclosures. BvT: Personal disclosures regarding consulting (Allogene, BMS/Celgene, Cerus, Incyte, IQVIA, Gilead Kite, Miltenyi, Novartis, Noscendo, Pentixapharm, Roche, Amgen, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite), honorarium (AstraZeneca, BMS, Incyte, Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme), financing of scientific studies (Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst)) and other financial relations (Travel support and congress fees: AbbVie, AstraZeneca, Gilead Kite, Merck Sharp & Dohme, Roche, Takeda, and Novartis). MD: No personal disclosures. DAE: Personal disclosures regarding honorarium (Sanofi-Genzyme, Takeda).